Designed for the Hand That Holds It: Human Factors and Use-Safety in Trial DHTs
Why usability and use-error are regulated concerns for participant-facing devices — and why the population, and the risk, set the bar.
REGULATORY OPERATIONSFund a summative usability evaluation of every critical task, on representative participants and the real device range, before enrollment.
Use-error in a participant-facing DHT is a regulated safety and data-quality risk, not polish — and it concentrates in the participants the trial most needs to hear from. Identify the critical tasks, set the evidence depth in the RIA, test on real users and real devices, and detect use-error in the field.
Five triggers raise the human-factors weight; each names its evidence
| If this is true of the deployment… | …the weight rises because | Evidence / mitigation |
|---|---|---|
| Participants self-administer a task that affects safety | Use-error can cause harm; critical-task analysis is engaged | Identify the critical tasks; run summative evaluation on them |
| The device captures data used in the analysis | Use-error degrades endpoint quality directly | Validate data-entry tasks on representative users; track missing data |
| The population is older, impaired, paediatric or low in literacy | The usability bar and evidence expectations rise | Representative users in formative and summative tests; accessibility |
| Use is unsupervised and remote | No site staff catch or correct use-errors | Error-tolerant flows and in-app guidance; monitor use-error signals |
| The app runs on a heterogeneous BYOD fleet | The validated interface is not the one each participant sees | Validate across the device / OS range; test accessibility settings |
Four positions that move usability from “polish” into the evidence plan
One mis-tap is three failures: a safety event, a missing or wrong data point in the endpoint, and a representativeness problem — use-error concentrates in the participants who struggle most.
IEC 62366-1 and MDR Annex I bind devices used by lay users. Where the DHT is not a device, FDA’s DHT guidance still requires a usability evaluation for the trial population.
A design a young, supervised, digitally fluent user navigates without error can defeat an older, impaired, paediatric or low-literacy participant using the device unsupervised at home.
Screen size, OS version, font-scaling, dark mode and accessibility settings change what each participant sees. A summative evaluation on one reference device does not cover the fleet.
Six actions that produce proportionate, defensible evidence
- 1Identify the critical tasks — separate the interactions that can cause harm or corrupt a key measurement from the rest.
- 2Right-size the evidence in the RIA — scale formative and summative work to task criticality and population difficulty.
- 3Test on real users and real devices — summative evaluation with representative participants across the BYOD range, not proxies.
- 4Specify and review the usability-engineering file — users, environment, use-related risk and evaluation record (QPP-06).
- 5Build a field path to detect use-error and feed it back into design and the Trigger Register (QPP-08).
- 6Protect representativeness — treat use-error as an equity issue so the data reflects the participants who struggle most (QPP-17).
IEC 62366-1 · ISO 14971 · EU MDR Annex I · FDA Applying Human Factors guidance (2016, revised Aug 2026) · FDA HF submission-content guidance (final May 2026) · QMSR · FDA DHT guidance · FDA decentralized-trials guidance · ICH E6(R3) Annex 2 · EMA computerized-systems guideline
© qointa 2026 – Public – Uncontrolled when printed · Not legal advice; this summary does not classify any device.
sales@qointa.com · qointa.com
More from the library
Digital Health Technologies in Clinical Trials — A Regulatory Position-Paper Series
One device, several perimeters: a framework for assessing the regulatory impact of the technologies a trial relies on.
Read more →Who Is the Manufacturer? Economic-Operator Roles in DHT Supply Chains
How provisioning, importing, kitting and modifying a device assign manufacturer, importer and distributor duties — often by operation of law.
Read more →You Can Delegate the Work, Not the Accountability: Vendor Qualification and Oversight under ICH E6(R3)
The sponsor’s duty to qualify and oversee its DHT vendors — distinct from who holds the economic-operator role.
Read more →Talk to a specialist
Bring one device and one protocol — a wearable, a sensor, an app, anything. We will tell you which regulatory perimeters it opens and what it takes to close them.
Book a 15-minute call